ERK1/2 is hyperactivated in in vitro and in vivo models with LMNA mutations, and recent findings have provided proof of principle for ERK1/2 inhibition as a therapeutic option to prevent or delay the onset of heart failure in patients with dilated cardiomyopathy caused by mutations in LMNA3–6. The gene discussed is MAPK3; the disease is heart failure.